Paragon Biosciences
Holding Companies & Conglomerates · Illinois, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
330 N Wabash Ave Ste 3500, Chicago, Illi...Phone Number
(312) 847-1350Website
www.paragonbiosci.comRevenue
$47.5 MillionIndustry
ZI Rank: 7
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
5
2
6
9
7
7
About Paragon Biosciences
Paragon Biosciences is a global leader in life sciences that focuses on creating, building, and funding innovative biology-based companies aimed at treating and curing diseases. Their portfolio includes companies like Emalex Biosciences, which is developing a new drug for Tourette syndrome, and Harmony Biosciences, which commercializes therapies for rare neurological diseases. Additionally, Evozyne utilizes generative AI to design novel protein therapeutics, while Castle Creek Biosciences specializes in regenerative medicine for severe skin and connective tissue disorders. CiRC Biosciences also contributes by developing regenerative medicines that restore function.Explore more
Paragon Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Paragon Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Paragon Biosciences recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Paragon Biosciences
Check out if Paragon Biosciences is spiking on competitors!
Product Launch: Get notified when Paragon Biosciences launches new products
Click to see if Paragon Biosciences had a recent Job posting/layoffs
Check if Paragon Biosciences has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Paragon Biosciences has new funding data
Paragon Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Paragon Biosciences as Masked Content
Find more new buyers
Compare Similar Companies to Paragon Biosciences
Compare insights from companies similar to Paragon Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Paragon Biosciences is experiencing very low activity levels compared to other companies in the Holding Companies & Conglomerates sector.
What does this means?
Paragon Biosciences is drawing exceptional interest within the Holding Companies & Conglomerates industry, suggesting notable developments or strong market momentum, learn more about Paragon Biosciences.
Paragon Biosciences financials insights
Gather financial insights about Paragon Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Other Financing Round
$71.8M
Paragon Biosciences Tech Stack
A closer look at the technologies used by Paragon Biosciences
See more technologies
Most Recent Scoops
Hiring Plans
Paragon Biosciences has more open roles in Engineering & Technical than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Open Position
Open Position
Open Position
Paragon Biosciences News & Media
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
CHICAGO--(BUSINESS WIRE)--Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with Tourette syndrome.Biotech Veteran Marc Yoskowitz Named Evozyne CEO
CHICAGO--(BUSINESS WIRE)--Chicago-based Evozyne today announced Marc Yoskowitz as CEO of the generative AI-driven biotech. Yoskowitz, most recently chief strategy officer and executive vice president, life sciences, at Tempus AI, will further develop the company’s strategy, focusing its generative AI platform on drug discovery in areas of high unmet patient need. Yoskowitz has held executive leadership positions with Pfizer, Hospira and McKinsey & Company, bringing deep biopharmaceutical, cEmalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate
CHICAGO--(BUSINESS WIRE)--Long-term safety data from pediatric patients treated with investigational drug ecopipam highlighted at Child Neurology Society Meeting in Vancouver.Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development
CHICAGO--(BUSINESS WIRE)--Chicago AI-powered biotech Evozyne closed $81 million in Series B funding led by OrbiMed and Fidelity, with participation from NVIDIA's NVentures.
Read more news
Top Holding Companies & Conglomerates Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Paragon Biosciences
Sign Up For FreeTo access detailed company insights
Paragon Biosciences is a global leader in life sciences that focuses on creating, building, and funding innovative biology-based companies aimed at treating and curing diseases. Their portfolio includes companies like Emalex Biosciences, which is developing a new drug for Tourette syndrome, and Harmony Biosciences, which commercializes therapies fo... Read More
